Months after Sanofi snapped up Kadmon for $1.9 billion, a longtime Kadmon consultant has been accused of using insider knowledge of the buyout to make more than $400,000 in illegal profits.
The SEC filed a complaint against Frank Glassner in a Manhattan federal court on Tuesday, charging him with insider...
